Friday, November 22, 2024

Canada’s Politics and Government News Source Since 1989

Friday, November 22, 2024 | Latest Paper

ISG Senator Rosemary Moodie

Ontario Senator Rosemary Moodie is a member of the Independent Senators Group.

Canada’s children face barriers to accessing safe and effective medications

Canadian children do not enjoy the same standards of safety, efficacy, availability, or access to drugs that Canadian adults enjoy. When it comes to

Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019

Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay

Canada’s children face barriers to accessing safe and effective medications

Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019

Canadian children do not enjoy the same standards of safety, efficacy, availability, or access to drugs that Canadian adults enjoy. When it comes to

Canada’s children face barriers to accessing safe and effective medications

Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019

Canadian children do not enjoy the same standards of safety, efficacy, availability, or access to drugs that Canadian adults enjoy. When it comes to

Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay

Canada’s children face barriers to accessing safe and effective medications

Canadian children do not enjoy the same standards of safety, efficacy, availability, or access to drugs that Canadian adults enjoy. When it comes to

Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019

Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay

Canada’s children face barriers to accessing safe and effective medications

Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019

Canadian children do not enjoy the same standards of safety, efficacy, availability, or access to drugs that Canadian adults enjoy. When it comes to

Canada’s children face barriers to accessing safe and effective medications

Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019

Canadian children do not enjoy the same standards of safety, efficacy, availability, or access to drugs that Canadian adults enjoy. When it comes to

Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay